Zacks.com on MSN4h
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
Cure Today4h
FDA Accepts sBLA For Opdivo Plus Yervoy For Some Patients with mCRC
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
pharmaphorum4h
Can Keytruda finally break into early head and neck cancer?
Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
Cancer vaccines have stumbled, but the approach is gaining new steam
For decades, researchers have worked to create drugs that teach the immune system to kill cancer cells the way traditional ...
Investing Snacks14h
Big Money Moves: Bristol-Myers Squibb Gains Investor Confidence
MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...